Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(Q1)Dec 28, 2024 | (FY)Sep 28, 2024 | (Q4)Sep 28, 2024 | (Q3)Jun 29, 2024 | (Q2)Mar 30, 2024 | (Q1)Dec 30, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jul 1, 2023 | (Q2)Apr 1, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -13.95%189.3M | 22.26%1.29B | 41.86%367M | 21.94%405.8M | 41.74%292.4M | -13.18%220M | -50.55%1.05B | 53.44%258.7M | 0.64%332.8M | 206.3M |
Net income from continuing operations | -18.46%201M | 73.14%789.5M | 97.13%178.6M | 580.25%194.5M | -22.24%169.9M | 31.54%246.5M | -64.98%456M | -23.67%90.6M | -117.73%-40.5M | --218.5M |
Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | 7,285.71%51.7M | ---- | ---- | ---- |
Depreciation and amortization | -16.29%74M | -4.45%309M | -1.19%74.6M | -10.96%72.3M | -8.79%73.7M | 2.91%88.4M | -24.81%323.4M | -29.17%75.5M | -25.78%81.2M | --80.8M |
Deferred tax | -10.80%-19.5M | 33.91%-72.1M | -122.47%-19.8M | 85.75%-5.5M | 17.51%-29.2M | 32.82%-17.6M | 34.36%-109.1M | 91.60%-8.9M | -106.42%-38.6M | ---35.4M |
Other non cash items | -169.45%-19.1M | 240.00%47.6M | 421.43%13.5M | 840.00%9.4M | 76.47%-2.8M | -5.50%27.5M | 302.90%14M | 4.55%-4.2M | 104.57%1M | ---11.9M |
Change In working capital | 51.08%-77.2M | 612.71%84.1M | 205.43%106.9M | 20.00%106.8M | 140.93%28.2M | -264.43%-157.8M | -97.40%11.8M | 1,490.91%35M | 888.89%89M | ---68.9M |
-Change in receivables | -9.16%-41.7M | 2,833.33%41M | -12.12%43.5M | -42.86%17.6M | 149.18%18.1M | 15.11%-38.2M | -100.55%-1.5M | -36.86%49.5M | -66.63%30.8M | ---36.8M |
-Change in inventory | -177.69%-36.1M | -867.35%-47.4M | -100.69%-300K | -319.74%-16.7M | -91.21%-17.4M | 72.34%-13M | 96.41%-4.9M | 187.55%43.6M | 112.58%7.6M | ---9.1M |
-Change in prepaid assets | 162.81%42.4M | -135.12%-14.4M | 5,690.91%63.7M | 135.55%49.7M | -138.34%-60.3M | -253.06%-67.5M | -88.64%41M | 116.18%1.1M | 11.64%21.1M | ---25.3M |
-Change in payables and accrued expense | 35.44%-18.4M | 356.99%95.6M | 138.41%10.6M | 73.08%45M | 280.74%68.5M | -1,339.13%-28.5M | -23.18%-37.2M | -184.54%-27.6M | 180.00%26M | ---37.9M |
-Change in other working capital | -120.75%-23.4M | -35.42%9.3M | 66.46%-10.6M | 220.00%11.2M | -51.99%19.3M | -560.87%-10.6M | 217.07%14.4M | -219.19%-31.6M | 137.63%3.5M | --40.2M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -13.95%189.3M | 22.26%1.29B | 41.86%367M | 21.94%405.8M | 41.74%292.4M | -13.18%220M | -50.55%1.05B | 53.44%258.7M | 0.64%332.8M | --206.3M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 78.89%-22M | -413.48%-781M | -963.75%-595.7M | -10.08%-42.6M | -134.76%-38.5M | -154.15%-104.2M | 26.27%-152.1M | -74.45%-56M | -294.90%-38.7M | -16.4M |
Capital expenditure reported | 25.99%-16.8M | 21.13%-72.4M | 54.82%-16.4M | 2.38%-20.5M | 31.55%-12.8M | -43.67%-22.7M | -30.03%-91.8M | -83.33%-36.3M | -42.86%-21M | ---18.7M |
Net PPE purchase and sale | 3.27%-14.8M | 1.03%-57.8M | 14.20%-13.9M | 13.55%-13.4M | -13.43%-15.2M | -15.04%-15.3M | -3.18%-58.4M | -37.29%-16.2M | -40.91%-15.5M | ---13.4M |
Net intangibles purchase and sale | ---15.4M | ---10M | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
Net business purchase and sale | 99.04%-300K | -6,472.00%-328.6M | -5,196.00%-254.8M | -325.00%-42.5M | --0 | ---31.3M | 96.85%-5M | --5M | -4,900.00%-10M | --0 |
Net investment purchase and sale | 175.36%26M | -3,002.00%-310.2M | ---- | ---- | ---5M | -245.00%-34.5M | ---10M | ---- | ---- | --0 |
Net other investing changes | -75.00%-700K | -115.27%-2M | -126.67%-400K | 295.45%4.3M | -135.03%-5.5M | 78.95%-400K | -83.52%13.1M | 400.00%1.5M | -113.66%-2.2M | --15.7M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 78.89%-22M | -413.48%-781M | -963.75%-595.7M | -10.08%-42.6M | -134.76%-38.5M | -154.15%-104.2M | 26.27%-152.1M | -74.45%-56M | -294.90%-38.7M | ---16.4M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 43.10%-537M | -129.43%-1.11B | 73.03%-56.8M | 5.29%-103.8M | 91.52%-4.2M | -731.54%-943.8M | 36.08%-483.2M | -24.03%-210.6M | 54.37%-109.6M | -49.5M |
Net issuance payments of debt | 96.08%-10.2M | -1,433.16%-291.3M | -134.09%-10.3M | -114.58%-10.3M | -108.00%-10.4M | -5,322.92%-260.3M | 91.05%-19M | -340.00%-4.4M | 98.08%-4.8M | ---5M |
Net common stock issuance | 23.57%-517.3M | -75.88%-835.1M | 72.40%-58.3M | 11.97%-100M | --0 | -576.80%-676.8M | 12.41%-474.8M | -20.62%-211.2M | ---113.6M | ---50M |
Proceeds from stock option exercised by employees | 28.42%12.2M | -12.09%37.8M | 137.74%12.6M | -26.88%6.8M | -33.08%8.9M | -37.09%9.5M | 28.36%43M | -19.70%5.3M | -3.13%9.3M | --13.3M |
Net other financing activities | -33.95%-21.7M | 38.27%-20M | -166.67%-800K | 40.00%-300K | 65.38%-2.7M | 31.93%-16.2M | 7.69%-32.4M | 0.00%-300K | -400.00%-500K | ---7.8M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 43.10%-537M | -129.43%-1.11B | 73.03%-56.8M | 5.29%-103.8M | 91.52%-4.2M | -731.54%-943.8M | 36.08%-483.2M | -24.03%-210.6M | 54.37%-109.6M | ---49.5M |
Net cash flow | ||||||||||
Beginning cash position | -21.61%2.16B | 17.79%2.76B | -11.79%2.44B | -15.58%2.18B | -20.86%1.93B | 17.79%2.76B | 99.91%2.34B | 16.41%2.77B | 12.72%2.58B | --2.44B |
Current changes in cash | 55.35%-369.7M | -245.32%-604.4M | -3,513.92%-285.5M | 40.60%259.4M | 77.85%249.7M | -937.21%-828M | -64.25%415.9M | 76.28%-7.9M | 128.62%184.5M | --140.4M |
Effect of exchange rate changes | -290.91%-8.4M | 2,866.67%8.9M | 571.43%6.6M | 82.35%-300K | -460.00%-1.8M | 51.72%4.4M | -94.83%300K | 44.00%-1.4M | -144.74%-1.7M | --500K |
End cash Position | -7.76%1.78B | -21.61%2.16B | -21.61%2.16B | -11.79%2.44B | -15.58%2.18B | -20.86%1.93B | 17.79%2.76B | 17.79%2.76B | 16.41%2.77B | --2.58B |
Free cash flow | -21.81%142.3M | 27.08%1.15B | 63.29%336.7M | 22.14%361.9M | 51.78%264.4M | -18.86%182M | -54.92%901M | 50.51%206.2M | -2.85%296.3M | --174.2M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |